Stocks · News reference
Featured presentations included 12-month clinical data reporting objective response rates of 97.5% among 40 patients treated with cryoablation plus endocrine therapy and 91.7% among 24 patients treated with cryoablation
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
IceCure Medical has successfully treated the first patient in its ChoICE post-marketing study, which evaluates the ProSense cryoablation system for treating low-risk breast cancer.
IceCure Medical has officially begun patient enrollment for its post-market clinical study of the ProSense cryoablation system for breast cancer at two U.S. sites.